Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.42 |
| ▸ | ITGAV | P06756 | 3/20 | 0.42 |
| ▸ | MC4R | P32245 | 4/20 | 0.36 |
| ▸ | MC5R | P33032 | 4/20 | 0.36 |
| ▸ | MC3R | P41968 | 4/20 | 0.36 |
| ▸ | MC1R | Q01726 | 4/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | TSLP | Q969D9 | 10/20 | 0.33 |
| ▸ | CTSG | P08311 | 2/20 | 0.33 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.33 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015503 | 0.98 | ITGB3 (0.41) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10015498 | 0.97 | ITGB3 (0.40) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10015492 | 0.93 | ITGB3 (0.38) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10015485 | 0.92 | ITGB3 (0.36) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10015489 | 0.90 | TSLP (0.38) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13007903 | 0.90 | KEAP1 (0.35) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10015507 | 0.89 | MC4R (0.36) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10015490 | 0.88 | TSLP (0.38) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL10015501 | 0.86 | ITGB3 (0.47) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12918070 | 0.86 | ITGB3 (0.47) | ITGB3ITGAVMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8834843-B2 | Imaging method | GE HEALTHCARE LIMITED (GB) | 2014-09-16 | — | — | US | disclosed |
| US-20100316565-A1 | NOVEL IMAGING METHOD | GE HEALTHCARE LIMITED (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100316565-A1 | NOVEL IMAGING METHOD | FABP1, SLC10A1, GLS2 | ITGB3 1382/4885ITGAV 1505/4885MC4R 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.